文献速递肝胆胰外科围术期管理与 ERAS

循环肿瘤DNA的肿瘤突变负荷预测肝细胞癌切除术后复发:一种新兴的监测生物标志物

Tumor Mutational Burden From Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection: An Emerging Biomarker for Surveillance.
PubMed 文献 · Ann Surg · 2024-06-11

本研究纳入2020年11月1日至2023年7月1日接受治愈性切除术的47例肝细胞癌患者,术后行循环肿瘤DNA检测。可检测到的肿瘤突变负荷与无复发生存期缩短相关(6.9 vs 14.7个月,P=0.049),且预测复发的曲线下面积优于甲胎蛋白(0.752 vs 0.550)。作者认为围术期循环肿瘤DNA可能是有用的监测工具,但需更大规模研究确认。

要点

  • 术后可检测到肿瘤突变负荷与无复发生存期缩短相关(6.9 vs 14.7个月,P=0.049)。
  • 肿瘤突变负荷预测复发的曲线下面积为0.752,甲胎蛋白为0.550。
  • 肿瘤突变负荷高与更差的无复发生存期相关(HR=5.386,95%CI:1.109-26.160,P=0.037)。

核心结论

  • 术后循环肿瘤DNA中可检测到的肿瘤突变负荷预测肝细胞癌复发,在该队列中优于甲胎蛋白。
  • 围术期循环肿瘤DNA可能是治愈性肝切除术后有用的监测工具。
  • 需要更大规模的研究来确认这一效用,并探索在肝细胞癌患者中的其他应用,包括对切除术后残留肿瘤突变负荷患者进行预防性治疗的潜力。

研究设计与样本

  • 研究纳入2020年11月1日至2023年7月1日接受治愈性切除术的肝细胞癌患者,使用Guardant360平台进行循环肿瘤DNA检测。
  • 肿瘤突变负荷计算为每兆碱基基因组物质中识别的体细胞突变数。
  • 共47例患者进行了术后循环肿瘤DNA检测,平均随访27个月,最长43.2个月。

主要发现

  • 12例患者(26%)出现复发。
  • 多数患者(41/47,87.2%)术后可识别循环肿瘤DNA;其中55.3%(26例)未检测到肿瘤突变负荷,45.7%(21例)可检测到肿瘤突变负荷。
  • 术后可识别的循环肿瘤DNA与无复发生存期无关(P=0.518)。
  • 可检测到的肿瘤突变负荷与无复发生存期缩短相关(6.9 vs 14.7个月,P=0.049)。
  • 肿瘤突变负荷患者复发率更高(9/21,42.9% vs 3/26,11.5%,P=0.02)。

关键数值与推荐

  • 肿瘤突变负荷预测复发的曲线下面积为0.752,甲胎蛋白为0.550。
  • ROC分析确立预测术后复发的肿瘤突变负荷截断值为4.8 mut/mB(P=0.002),预测无复发生存期的截断值同样为4.8 mut/mB(P=0.025)。
  • 甲胎蛋白与无复发生存期无关:实验室正常截断值<11 ng/mL(P=0.682)或ROC分析确立的截断值≥4.6 ng/mL(P=0.494)。
  • Cox回归分析显示肿瘤突变负荷高与更差的无复发生存期相关(HR=5.386,95%CI:1.109-26.160,P=0.037),而微血管侵犯(P=0.853)和甲胎蛋白(P=0.439)则无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大规模的研究来确认这一效用,并探索在肝细胞癌患者中的其他应用,包括对切除术后残留肿瘤突变负荷患者进行预防性治疗的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Describe the utility of circulating tumor DNA in the postoperative surveillance of hepatocellular carcinoma (HCC). BACKGROUND: Current biomarkers for HCC like alpha-fetoprotein (AFP) are lacking. Circulating tumor DNA (ctDNA) has shown promise in colorectal and lung cancers, but its utility in HCC remains relatively unknown. METHODS: Patients with HCC undergoing curative-intent resection from November 1, 2020, to July 1, 2023, received ctDNA testing using the Guardant360 platform. Tumor mutational burden (TMB) is calculated as the number of somatic mutations-per-megabase of genomic material identified. RESULTS: Forty-seven patients had postoperative ctDNA testing. The mean follow-up was 27 months, and the maximum was 43.2 months. Twelve patients (26%) experienced recurrence. Most (n=41/47, 87.2%) had identifiable ctDNA postoperatively; 55.3% (n=26) were TMB-not detected versus 45.7% (n=21) TMB-detectable. Postoperative identifiable ctDNA was not associated with RFS ( P =0.518). Detectable TMB was associated with reduced RFS (6.9 vs 14.7 mo, P =0.049). There was a higher rate of recurrence in patients with TMB (n=9/21, 42.9%, vs n=3/26, 11.5%, P =0.02). Area under the curve for TMB-prediction of recurrence was 0.752 versus 0.550 for AFP. ROC analysis established a TMB cutoff of 4.8mut/mB for predicting post-operative recurrence ( P =0.002) and RFS ( P =0.025). AFP was not correlated with RFS using the lab-normal cutoff (<11 ng/mL, P =0.682) or the cutoff established by ROC analysis (≥4.6 ng/mL, P =0.494). TMB-high was associated with poorer RFS on cox-regression analysis (hazard ratio=5.386, 95% CI: 1.109-26.160, P =0.037), while microvascular invasion ( P =0.853) and AFP ( P =0.439) were not. CONCLUSIONS: Identifiable TMB on postoperative ctDNA predicts HCC recurrence and outperformed AFP in this cohort. Perioperative ctDNA may be a useful surveillance tool following curative-intent hepatectomy. Larger-scale studies are needed to confirm this utility and investigate additional applications in HCC patients, including the potential for prophylactic treatment in patients with residual TMB after resection.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Wehrle CJ, Hong H, Kamath S, et al. Tumor Mutational Burden From Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection: An Emerging Biomarker for Surveillance. Ann Surg. 2024. PMID: 38860385. doi:10.1097/SLA.0000000000006386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。